Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept as a Non-nephrotoxic Immunosuppressant in Cardiac Transplant Patients at Risk of Chronic Renal Failure
2024-516541-40-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Sep 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of belatacept in primary graft dysfunction (PGD) and chronic kidney disease (CKD) (2 arms), sponsored by CHU de Nantes. Planned start Sep 2024; status: authorised.
02
Drugs
belatacept
03
Conditions
primary graft dysfunction (PGD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-516541-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516541-40-00.